# REPLIGEN CORP (RGEN)

Informational only - not investment advice.

CIK: 0000730272
SIC: 2836 Biological Products, (No Diagnostic Substances)
SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2836 Biological Products, (No Diagnostic Substances)](/industry/2836/)
Latest 10-K filed: 2026-02-26
SEC page: https://www.sec.gov/edgar/browse/?CIK=730272
Filing source: https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-26 · accession 0001193125-26-076528 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000730272.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 738,256,000 USD | 2025 | verified |
| Net income | 48,894,000 USD | 2025 | verified |
| Assets | 2,949,699,000 USD | 2025 | verified |
| Free cash flow | 93,898,000 USD | 2025 | computed |
| Net margin | 6.62% | 2025 | computed |
| Operating margin | 7.47% | 2025 | computed |
| Revenue YoY | +16.36% | 2025 | computed |
| ROE | 2.32% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | RGEN | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | 6.6% | -14.7% | 59 | 33 |
| Operating margin | 7.5% | -16.8% | 61 | 32 |
| Revenue growth | 16.4% | 20.9% | 39 | 42 |
| FCF margin | 12.7% | -127.6% | 79 | 43 |
| ROE | 2.3% | -38.7% | 81 | 60 |
| ROA | 1.7% | -30.4% | 80 | 66 |
| Liabilities / equity | 0.40 | 0.38 | 56 | 62 |
| Current ratio | 8.37 | 5.52 | 69 | 66 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2836 Biological Products, (No Diagnostic Substances), not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 738256000 | USD | 2025 | 2026-02-26 |
| Net income | 48894000 | USD | 2025 | 2026-02-26 |
| Assets | 2949699000 | USD | 2025 | 2026-02-26 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-26. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000730272.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 104,541,000 | 141,236,000 | 194,032,000 | 270,245,000 | 366,260,000 | 670,534,000 | 801,536,000 | 632,362,000 | 634,439,000 | 738,256,000 |
| Net income | 11,681,000 | 28,353,000 | 16,617,000 | 21,411,000 | 59,926,000 | 128,291,000 | 185,959,000 | 35,596,000 | -25,514,000 | 48,894,000 |
| Operating income | 15,974,000 | 14,005,000 | 25,988,000 | 36,083,000 | 69,823,000 | 167,249,000 | 224,670,000 | 47,703,000 | -35,114,000 | 55,167,000 |
| Diluted EPS | 0.34 | 0.72 | 0.37 | 0.44 | 1.11 | 2.24 | 3.24 | 0.63 | -0.46 | 0.86 |
| Operating cash flow | 7,521,000 | 17,451,000 | 32,770,000 | 67,216,000 | 62,625,000 | 119,016,000 | 172,083,000 | 113,918,000 | 175,394,000 | 117,417,000 |
| Capital expenditures | 4,325,000 | 5,454,000 | 10,635,000 | 18,504,000 | 22,455,000 | 67,089,000 | 84,834,000 | 36,222,000 | 25,677,000 | 23,519,000 |
| Share buybacks |  |  |  |  |  | 0.00 | 0.00 | 14,386,000 | 0.00 | 0.00 |
| Assets | 288,913,000 | 743,519,000 | 774,621,000 | 1,400,113,000 | 1,902,887,000 | 2,358,354,000 | 2,531,600,000 | 2,831,185,000 | 2,829,666,000 | 2,949,699,000 |
| Liabilities |  | 151,971,000 | 159,053,000 | 340,345,000 | 373,737,000 | 608,287,000 | 620,900,000 | 866,340,000 | 856,948,000 | 843,570,000 |
| Stockholders' equity | 168,764,000 | 591,548,000 | 615,568,000 | 1,059,768,000 | 1,529,150,000 | 1,750,067,000 | 1,910,700,000 | 1,964,845,000 | 1,972,718,000 | 2,106,129,000 |
| Cash and cash equivalents | 122,233,000 | 173,759,000 | 193,822,000 | 528,392,000 | 717,292,000 | 603,814,000 | 523,458,000 | 751,323,000 | 757,355,000 | 566,021,000 |
| Free cash flow | 3,196,000 | 11,997,000 | 22,135,000 | 48,712,000 | 40,170,000 | 51,927,000 | 87,249,000 | 77,696,000 | 149,717,000 | 93,898,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin | 11.17% | 20.07% | 8.56% | 7.92% | 16.36% | 19.13% | 23.20% | 5.63% | -4.02% | 6.62% |
| Operating margin | 15.28% | 9.92% | 13.39% | 13.35% | 19.06% | 24.94% | 28.03% | 7.54% | -5.53% | 7.47% |
| Return on equity | 6.92% | 4.79% | 2.70% | 2.02% | 3.92% | 7.33% | 9.73% | 1.81% | -1.29% | 2.32% |
| Return on assets | 4.04% | 3.81% | 2.15% | 1.53% | 3.15% | 5.44% | 7.35% | 1.26% | -0.90% | 1.66% |
| Liabilities / equity |  | 0.26 | 0.26 | 0.32 | 0.24 | 0.35 | 0.32 | 0.44 | 0.43 | 0.40 |
| Current ratio | 8.74 | 9.63 | 2.12 | 13.28 | 2.83 | 2.48 | 2.47 | 6.74 | 8.41 | 8.37 |

## As-reported value updates

5 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/RGEN/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-07-29. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000730272.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | 0.71 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | 0.51 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | 0.35 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 141,192,000 | 18,172,000 | 0.32 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 155,743,000 | -25,488,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 151,346,000 | 2,094,000 | 0.04 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 158,839,000 | 5,713,000 | 0.10 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 154,871,000 | -654,000 | -0.01 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 167,547,000 | -33,869,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 169,172,000 | 5,830,000 | 0.10 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 182,366,000 | 14,866,000 | 0.26 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 188,805,000 | 14,911,000 | 0.26 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 197,913,000 | 13,287,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 194,255,000 | 8,333,000 | 0.15 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 204,128,000 | 5,008,000 | 0.09 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from RGEN's latest 10-K: [/company/RGEN/business/](/company/RGEN/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from RGEN's latest 10-K: [/company/RGEN/risk-factors/](/company/RGEN/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/730272/000119312526323773/rgen-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-07-29
Report date: 2026-06-30

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

Repligen and its subsidiaries, collectively doing business as Repligen Corporation (“Repligen”, “we”, “our”, or the “Company”) is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.

As the overall market for biologics continues to grow and expand, our customers – primarily large biopharmaceutical companies and contract development and manufacturing organizations (“CDMOs”) and other life sciences companies (integrators) – face critical production cost, capacity, quality and time pressures. Our products help enable customers to address these concerns, both accelerating development and improving yields. We are committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs – including monoclonal antibodies (“mAbs”) and mAb derivatives like antibody drug conjugates, recombinant proteins, RNA-based therapeutics and vaccines and cell and gene therapies – that are improving human health worldwide. For more information regarding our business, products and acquisitions, see Part I, Item 1, “Business”, included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the Securities and Exchange Commission (“SEC”) on February 26, 2026 (“Form 10-K”).

We currently operate as one bioprocessing business, with a comprehensive suite of products to serve both upstream and downstream processes in biological drug manufacturing. Building on over 40 years of industry expertise, we have developed a broad and diversified product portfolio that reflects our passion for innovation and the customer-first culture that drives our entire organization. We continue to capitalize on opportunities to maximize the value of our product platform through both organic growth initiatives (internal innovation and commercial leverage) and targeted acquisitions.

Macroeconomic Trends

As a result of our global presence, a significant portion of our revenue and expenses is denominated in currencies other than the United States (“U.S.”) dollar. We are therefore subject to non-U.S. exchange exposure. Exchange rates can be volatile and a substantial weakening or strengthening of foreign currencies against the U.S. dollar could increase or reduce our revenue and gross profit margin and impact the comparability of results from period to period.

We have experienced, and expect to continue to experience, cost inflation, primarily in raw materials and other supply chain costs, as a result of global macroeconomic trends, including global geopolitical conflicts and labor shortages. Actions taken to mitigate supply chain disruptions and inflation, including price increases and productivity improvements, have generally been successful in offsetting the impact of these trends.

On February 20, 2026, the U.S. Supreme Court rendered a decision invalidating tariffs imposed by the Trump administration under the International Emergency Economic Powers Act (“IEEPA”). This decision introduces uncertainty regarding future trade policy actions and could impact our cost structure and supply-chain planning. We will continue to monitor the effects of tariffs implemented by the Trump administration and the potential imposition of modified or additional tariffs.

19

Table of Contents

Acquisitions

On July 21, 2026, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) to acquire all of the outstanding shares of common stock of BioLife Solutions, Inc. (“BioLife”), a publicly traded company focused on developing cell processing tools and services for the cell and gene therapy market, for approximately $1.5 billion, comprised of approximately 64% in our common stock and 36% in cash (the “Transaction”). We will account for the acquisition in the period the Transaction closes, which closing is expected to occur in the fourth quarter of 2026. We expect that the cash portion of the merger consideration will be funded with cash and cash equivalents on hand.

At the closing of the Transaction, BioLife stockholders will be entitled to $11.25 in cash per share plus 0.1442 shares of Repligen common stock per BioLife share. The Transaction is subject to customary closing conditions, including (among others) (i) the adoption and approval of the Merger Agreement by the holders of a majority of the outstanding shares of BioLife common stock; (ii) the absence of any adverse law or order that restrains, enjoins, makes illegal or otherwise prohibits the consummation of the Transaction; (iii) the shares of our common stock to be issued in connection with the Transaction (the “Merger Shares”) being approved for listing on The Nasdaq Stock Market; (iv) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; (v) the U.S. Securities and Exchange Commission (the “SEC”) having declared effective the Registration Statement on Form S-4 to be filed by Repligen to register the Merger Shares; (vi) subject to certain materiality exceptions, the accuracy of certain representations and warranties of each of Repligen and BioLife contained in the Merger Agreement and the compliance by each party with the covenants contained in the Merger Agreement; and (vii) the absence of a continuing material adverse effect with respect to each of Repligen and BioLife. The Transaction with BioLife will bring a differentiated portfolio of products including a market-leading bio preservation media platform and other cell processing tools while expanding our presence in the cell therapy market.

On March 4, 2025, we completed our acquisition of 908 Devices Inc.’s (“908 Devices”) desktop portfolio of four devices for bioprocessing process analytical technology applications (“PAT Portfolio,” together with 908 Devices, the “908 Devices PAT Portfolio”). In connection with the transaction, we also acquired facilities, employees, equipment and lease obligations for facilities in North Carolina and Braunschweig, Germany as well as certain working capital balances related to the PAT Portfolio. The addition of these desktop assets complements and strengthens our differentiated PAT Portfolio that provides its biopharmaceutical and CDMO customers with actionable insights to optimize development processes and improve manufacturing efficiencies.

Critical Accounting Policies and Estimates

The preparation of our financial statements and related disclosures require us to make estimates, assumptions and judgments. There have been no material changes to our critical accounting policies since December 31, 2025. For a description of our critical accounting policies that affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements, refer to Note 2, “Summary of Significant Accounting Policies” included in Part II, Item 8, “Financial Statements and Supplementary Data” to the Company's Form 10-K.

Recent Accounting Pronouncements

For information about recent accounting pronouncements, refer to Note 1, “Summary of Significant Accounting Policies,” included in Part I, Item 1, “Financial Statements,” in this Quarterly Report on Form 10-Q.

Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with the accompanying condensed consolidated financial statements and the related footnotes in this Quarterly Report on Form 10-Q. All dollar and percentage changes made herein refer to the three and six months ended June 30, 2026, compared with the three and six months ended June 30, 2025, unless otherwise noted. Certain prior year amounts have been reclassified to conform with the current year presentation.

Revenues

Total revenues for the three and six months ended June 30, 2026 and 2025 were as follows:

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,","","","Six Months Ended June 30,"],["","","2026","","","2025","","","$ Change","","","% Change","","","2026","","","2025","","","$ Change","","","% Change"],["","","(Amounts in thousands)"],["Revenue:"],["Product","","$","204,085","","","$","182,329","","","$","21,756","","","","11.9","%","","$","398,296","","","$","351,466","","","$","46,830","","","","13.3","%"],["Royalty and other revenue","","","43","","","","37","","","","6","","","","16.2","%","","","87","","","","72","","","","15","","","","20.8","%"],["Total revenue","","$","204,128","","","$","182,366","","","$","21,762","","","","11.9","%","","$","398,383","","","$","351,538","","","$","46,845","","","","13.3","%"]]
[[/GREPCENT_TABLE]]

20

Table of Contents

Product revenues

During the three and six months ended June 30, 2026, product revenue increased by $21.8 million, or 11.9%, and $46.8 million, or 13.3%, respectively, as compared to the same period in 2025. This growth is widespread across our portfolio of products and includes contributions from all our franchises.

During the three months ended June 30, 2026, product revenue increased 43.3% in Asia Pacific and the rest of the world and 17.3% in North America, and decreased 6.1% in Europe. During the six months ended June 30, 2026, product revenue increased 36.1% in Asia Pacific and the rest of the world, 11.2% in North America, and 7.2% in Europe.

Product revenues were comprised of the following:

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,","","","Six Months Ended June 30,"],["","","2026","","","2025","","","2026","","","2025"],["","","(Amounts in thousands)"],["Filtration products","","$","95,654","","","$","94,678","","","$","191,495","","","$","186,742"],["Chromatography products","","","51,875","","","","46,622","","","","93,017","","","","79,037"],["Process analytics products","","","25,820","","","","19,680","","","","49,377","","","","35,180"],["Proteins products","","","31,375","","","","20,908","","","","64,178","","","","49,767"],["Other","","","(639",")","","","441","","","","229","","","","740"],["Total product revenue","","$","204,085","","","$","182,329","","","$","398,296","","","$","351,466"]]
[[/GREPCENT_TABLE]]

Royalty and other revenues

Royalty and other revenues in the three and six months ended June 30, 2026 and 2025 relate to royalties received from a third-party systems manufacturer associated with our OPUS® chromatography columns. Royalty revenues are variable and are dependent on sales generated by our partners.

Costs and operating expenses

Total costs and operating expenses for the three and six months ended June 30, 2026 and 2025 were comprised of the following:

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm
Complete FY 2025 MD&A: /company/RGEN/mda/fy2025/

Extracted from a substantive MD&A body after the formal Item 7 span was a TOC or reference stub.
Confidence: high
Filing date: 2026-02-26
Report date: 2025-12-31

Results of Operations

The following discussion of the financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and the related footnotes, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this Annual Report on Form 10-K. All dollar and percentage changes made herein refer to the year ended December 31, 2025, compared with the year ended December 31, 2024, unless otherwise noted.

Revenues

Total revenues were comprised of the following:

[[GREPCENT_TABLE]]
[["","","Year Ended December 31,"],["","","2025","","","2024","","","$ Change","","","% Change"],["","","(Amounts in thousands)"],["Revenue:"],["Product","","$","737,960","","","$","634,178","","","$","103,782","","","","16.4","%"],["Royalty and other revenue","","","296","","","","261","","","","35","","","","13.4","%"],["Total revenue","","$","738,256","","","$","634,439","","","$","103,817","","","","16.4","%"]]
[[/GREPCENT_TABLE]]

Product revenue

We are continuously focused on selling our products directly to customers in the life sciences and pharmaceutical industries, including CDMOs. These direct sales have represented 90.8% of our total product revenue during 2025 compared to 89.7% of our total product revenue in 2024. Sales of our bioprocessing products can be impacted by the timing of large-scale production orders which may result in significant quarterly fluctuations.

Product revenues were comprised of the following:

[[GREPCENT_TABLE]]
[["","","Year Ended December 31,"],["","","2025","","","2024"],["","","(Amounts in thousands)"],["Filtration products","","$","402,792","","","$","372,963"],["Chromatography products","","","153,176","","","","122,810"],["Process analytics products","","","81,237","","","","59,301"],["Proteins products","","","97,435","","","","74,425"],["Other","","","3,320","","","","4,679"],["Total product revenue","","$","737,960","","","$","634,178"]]
[[/GREPCENT_TABLE]]

Revenue from the sale of our products which make up our filtration, chromatography, process analytics and proteins franchises comes from the sale of a number of products as described in Part I, Item 1. “Business - Our Products” of this report.

In 2025, product revenue increased by $103.8 million, or 16.4% , compared to 2024. This growth is widespread across our portfolio of products and includes significant contributions from all our franchises. Geographically, product revenue increased 15.7% in North America, 16.0% in Europe and 19.3% in Asia Pacific and the rest of the world. Related to our acquisitions, products acquired from

30

Table of Contents

908 Devices contributed $9.3 million in revenue during the year ended December 31, 2025. In addition, the year ended December 31, 2024 included $11.5 million of COVID-19 related sales.

Royalty and other revenue

Royalty and other revenue for all periods presented relate to royalties received from a third-party systems manufacturer associated with our OPUS® chromatography columns. Royalty revenues are variable and are dependent on sales generated by our partners.

Costs and operating expenses

Total costs and operating expenses for the years ended December 31, 2025 and 2024 were comprised of the following:

[[GREPCENT_TABLE]]
[["","","Year Ended December 31,"],["","","2025","","","2024","","","$ Change","","","% Change"],["","","(Amounts in thousands)"],["Cost of goods sold","","$","352,011","","","$","359,794","","","$","(7,783",")","","","(2.2",")%"],["Research and development","","","54,177","","","","43,200","","","","10,977","","","","25.4","%"],["Selling, general and administrative","","","290,508","","","","263,368","","","","27,140","","","","10.3","%"],["Change in fair value of contingent consideration","","","(13,607",")","","","3,191","","","","(16,798",")","","","(526.4",")%"],["Total costs and operating expenses","","$","683,089","","","$","669,553","","","$","13,536","","","","2.0","%"]]
[[/GREPCENT_TABLE]]

Cost of goods sold

In 2025, cost of goods sold decreased $7.8 million, or 2.2%, compared to 2024. The decrease in cost of goods sold is primarily due to lower costs related to scrap, excess and obsolete inventory and restructuring activities in 2025, compared to those incurred in 2024. Restructuring relates to activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations. These decreases were partially offset by higher export duties, direct material and labor costs.

In 2025, gross margin was 52.3%, compared to 43.3% in 2024. The increase in gross margin resulted from the decrease in cost of goods sold as described above.

See Note 5, “Restructuring Activities and Other Inventory-Related Charges” in the notes to the consolidated financial statements, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this Annual Report on Form 10-K, for more detail.

Research and development expenses

Research and development expenses (“R&D”) expenses are related to the development of products supporting bioprocessing operations, which include personnel compensation, supplies and other research expenses. Due to the fact that these various programs share personnel and fixed costs, we have not provided historical costs incurred by project.

In 2025, R&D expenses increased $11.0 million, or 25.4%, compared to 2024. The increase in R&D costs is primarily driven by the 908 Devices PAT Portfolio and Tantti acquisitions, which have been included in our consolidated results of operations since the acquisition dates of March 2025 and December 2024, respectively.

Selling, general and administrative expenses

Selling, general and administrative (“SG&A”) expenses include the costs associated with selling our commercial products and costs required to support our marketing efforts. It also includes legal, accounting, patent, shareholder services, amortization of intangible assets and other administrative functions.

In 2025, SG&A costs increased $27.1 million, or 10.3%, compared to 2024. The increase in SG&A is primarily driven by an investment in personnel costs to support growth, increased headcount, and incremental professional services, primarily driven by our acquisition and integration activities. These increases were partially offset by the incremental stock-based compensation expense incurred during 2024 associated with the modification of our former Chief Executive Officer’s (“CEO”) unvested equity awards in connection with their transition from CEO to Executive Chair of our Board of Directors. See Note 11, “Stockholders' Equity” included within Item 15, “Exhibits and Financial Statement Schedules”, in this Annual Report on Form 10-K for more information.

Contingent consideration

Change in fair value of contingent consideration represents the change in fair value of the obligation included in current and noncurrent contingent consideration on the consolidated balance sheets as of the end of each period. Remeasurement of the contingent consideration obligation is done each quarter and the carrying value of the obligation is adjusted to the current fair value through our condensed consolidated statements of comprehensive income. The changes during 2025 compared to 2024 were related to revisions to the amount and expected timing of future revenues underlying certain contingent payments and a change in market inputs used to calculate the discount rate.

31

Table of Contents

Other income, net

The table below provides detail regarding our other income, net:

[[GREPCENT_TABLE]]
[["","","Year Ended December 31,"],["","","2025","","","2024","","","$ Change","","","% Change"],["","","(Amounts in thousands)"],["Investment income","","$","27,574","","","$","35,827","","","$","(8,253",")","","","(23.0",")%"],["Interest expense","","","(21,513",")","","","(20,731",")","","","(782",")","","","3.8","%"],["Amortization of debt issuance costs","","","(1,660",")","","","(1,843",")","","","183","","","","(9.9",")%"],["Other income (expense), net","","","2,815","","","","(5,174",")","","","7,989","","","","(154.4",")%"],["Other income, net","","$","7,216","","","$","8,079","","","$","(863",")","","","(10.7",")%"]]
[[/GREPCENT_TABLE]]

Investment income

Investment income includes income earned on cash, cash equivalents and marketable securities. Our investment income decreased $8.3 million in 2025, compared to 2024 due to a reduction in interest rates and varying average cash and marketable securities balances during the period. We expect investment income to vary based on changes in the amount of funds invested and fluctuation of interest rates.

Interest expense

Interest expense increased $0.8 million in 2025, compared to the same period of 2024. Interest expense includes contractual coupon interest on our outstanding convertible notes and the associated accretion of the discount. The discount is being accreted into interest expense using the effective interest method over the term of the 2023 Notes, as defined below. See Note 13, “Convertible Senior Notes” in the notes to the consolidated financial statements, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this Annual Report on Form 10-K for more detail.

Amortization of debt issuance costs

Transaction costs related to the issuance of the 2019 Notes and the 2023 Notes, as defined below, are amortized and recorded within amortization of debt issuance costs on the consolidated statements of comprehensive income.

Other income (expense), net

Other income (expense), net increased $8.0 million in 2025, compared to the same period in 2024. Other income (expense), net primarily includes the changes in foreign currency transaction gains and losses, revaluation impact of intercompany loans with subsidiaries and unrealized and realized impacts of foreign exchange forward contracts.

Income tax provision (benefit)

Income tax provision (benefit) was as follows:

[[GREPCENT_TABLE]]
[["","","Year Ended December 31,"],["","","2025","","","2024","","","$ Change","","","% Change"],["","","(Amounts in thousands)"],["Income tax provision (benefit)","","$","13,489","","","$","(1,521",")","","$","15,010","","","","(986.9",")%"],["Effective tax rate","","","21.6","%","","","5.6","%"]]
[[/GREPCENT_TABLE]]

For year ended December 31, 2025, we recorded an income tax provision of $13.5 million. The effective tax rate was 21.6% for 2025 and is based upon the income for the year ended December 31, 2025 and the composition of income in different jurisdictions.

The difference in effective tax rates between the periods was primarily due to the increase in income before income taxes, nontaxable contingent consideration, lower nondeductible stock-based compensation and an increase in valuation allowance offset by stock windfall tax benefits. Our effective tax rate for the year ended December 31, 2025 was more than the U.S. statutory rate of 21% primarily due to an increase in valuation allowance offset by nontaxable contingent consideration and stock windfall tax benefits.

On July 4, 2025, the United States enacted into law new tax legislation, the One Big Beautiful Bill Act (“OBBBA”), which contains several provisions modifying the corporate income tax code such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, updates to the international tax framework and the reinstatement of certain business-related provisions. The legislation has multiple effective dates, with provisions taking effect from 2025 through 2027. The changes effective in 2025 are included in our provision for income taxes for the year ended December 31, 2025 and were not material. We do not expect the OBBBA to have a material impact on our consolidated financial statements or results of operations in future periods.

See Note 10, “Income Taxes” in the notes to the consolidated financial statements, included within Part IV, Item

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/RGEN/mda/fy2025/
All MD&A years: /company/RGEN/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/RGEN/mda/fy2024/): filed 2025-03-14; accession 0000950170-25-038999 (https://www.sec.gov/Archives/edgar/data/730272/000095017025038999/rgen-20241231.htm)
- [FY 2023 MD&A](/company/RGEN/mda/fy2023/): filed 2024-02-22; accession 0000950170-24-018809 (https://www.sec.gov/Archives/edgar/data/730272/000095017024018809/rgen-20231231.htm)
- [FY 2022 MD&A](/company/RGEN/mda/fy2022/): filed 2023-02-22; accession 0000950170-23-003793 (https://www.sec.gov/Archives/edgar/data/730272/000095017023003793/rgen-20221231.htm)
- [FY 2021 MD&A](/company/RGEN/mda/fy2021/): filed 2022-02-17; accession 0000950170-22-001430 (https://www.sec.gov/Archives/edgar/data/730272/000095017022001430/rgen-20211231.htm)


## FDA-approved drug applications

Applications listed under this company's exact-matched sponsor name. Approved applications only.

No resolved FDA applications were found for this company under the exact-unique, approved-only publish rule.

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent.


## Macro cross-references

Indicators mapped to this company's SIC classification (industry 2836 Biological Products, (No Diagnostic Substances)) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/RGEN.md · JSON record: /company/RGEN.json · verified financials: /company/RGEN/financials.json / /company/RGEN/financials.csv · machine TOC for the whole site: /llms.txt